Centauri Therapeutics Ltd, a Sandwich, UK-based biotechnology company focused on the treatment of infectious diseases, raised £3m in funding.
Backers included Animatrix Capital LLP, a regional investment fund, and private investors.
The company intends to use the funds to develop its first lead Alphamers against anti-microbial resistant (AMR) pathogens.
Led by Mike Westby, CEO, Centauri Therapeutics, Centauri has also acquired the Alphamer technology for drug discovery and development from Altermune Technologies LLC, and the rights to patents, proprietary compounds, know-how and collaboration/licence agreements in exchange for an undisclosed fee.
The company has also appointed Dr Clive Dix as Chairman. Dix was formerly co-founder and Chief Executive of Convergence Pharmaceuticals Ltd., acquired by Biogen Idec in 2015 in a deal worth up to $675m. Previously, he was a founder and CEO of PowderMed Ltd, acquired by Pfizer in 2006; and Chairman of Auralis Ltd where he managed a successful US trade sale. Before that Dix was a main Board Director of PowderJect Pharmaceuticals plc until its acquisition by Chiron in 2003.
Centauri Therapeutics has established and is based at a core R&D facility at Discovery Park in Sandwich, Kent.